The findings are published in July’s issue of Clinical Pharmacology & Therapeutics, the flagship journal of the American Society of Clinical Pharmacology & Therapeutics.

University of Florida researchers determined an FDA-approved program deters pregnant women from starting a potentially harmful immunosuppressive drug. But for women taking the drug, the program was not effective at reducing conception.

Winterstein is the first faculty member from the UF College of Pharmacy to lead the International Society for Pharmacoepidemiology.

The State University System of Florida Board of Governors has selected the University of Florida to lead a statewide consortium studying health outcomes related to medical marijuana. UF will lead the Consortium for Medical Marijuana Clinical Outcomes Research, which will be composed of public and private universities engaged in research…

A new study by University of Florida researchers questions the accuracy of the criteria used by the Centers for Medicare and Medicaid Services to identify patients at risk of opioid abuse and overdose.

A pair of Orlando pharmacy students also placed in the top 10 of the Clinical Skills Challenge at ASHP Midyear.

As president-elect, Winterstein will serve on the executive board and chair the strategic planning committee. She joined ISPE in 2000 and has held numerous leadership roles during the past two decades.

Larisa Cavallari, Margaret James, Jatinder Lamba and Almut Winterstein will serve three-year terms beginning in the 2019 academic year.

The nearly $3 million grant will enhance the FDA’s capability to conduct drug safety studies on maternal and infant outcomes involving exposure to medications during pregnancy.

The grant from the Bill & Melinda Gates Foundation will help prevent unintended pregnancies.